Table 1.

An overview of the combinations of medicines used in COVID-19 therapy.

Medicines	Reference
Lopinavir/ritonavir	Cao et al. (2020)
Lopinavir/ritonavir + umifenovir	Deng et al. (2020)
Lopinavir/ritonavir + interferon beta	Momattin et al. (2019)
Lopinavir/ritonavir + interferon beta + umifenovir	Jaihua et al. (2020)
Hydroxychloroquine + azithromycin	Gautret et al. (2020)
Lopinavir/ritonavir + interferon alpha-2b	(Lythgoe and Middleton, 2020)*
Interferon alpha + umifenovir	(Lythgoe and Middleton, 2020)*
lopinavir/ritonavir + ribavirin + interferon beta-1b	(Lythgoe and Middleton, 2020)*
Lopinavir/ritonavir + novaferon	(Zhang et al., 2020)*
Favipiravir + interferon-alpha	(Zhang et al., 2020)*
ASC09F + ritonavir + oseltamivir	(Zhang et al., 2020)*
Favipiravir + baloxavir + marboxil	(Zhang et al., 2020)*
Lopinavir/ritonavir + interferon alpha + glucocorticoid	(Zhang et al., 2020)*
Lopinavir/ritonavir + umifenovir + novaferon	(Zhang et al., 2020)*
Hydroxychloroquine + umifenovir	(Zhang et al., 2020)*
Favipiravir + bromhexin + umifenovir + interferon alpha-2b	(Mina et al., 2020)*
Favipiravir + tocilizumab	(Mina et al., 2020)*
ASC09 + oseltamivir	(Mina et al., 2020)*
Darunavir + cobicistat + thymosin	(Mina et al., 2020)*

*Ongoing clinical trial, ASC09F - a new protease inhibitor.